Back to Directory Gregory Gardiner Email gregory.x.gardiner@gsk.com Phone 44(0)7920052635 Institution GSK Title Safety Scientist Address GSK HQ 79 New Oxford Street WC1A 1DG , United Kingdom Request an Update Affiliated Studies IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Closed to Follow Up
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Closed to Follow Up